Ulcerative Colitis

SAN ANTONIO — In this video from the American College of Gastroenterology Annual Meeting, David T. Rubin, MD, section chief of Gastroenterology, Hepatology and Nutrition, and co-director of the Digestive Diseases Center at the University of Chicago Medicine, discusses his presentation on identifying and managing patients with high-risk ulcerative colitis.

News that Stelara — a treatment that has been commercially available to treat Crohn’s disease for more than 3 years — was approved by the FDA to treat ulcerative colitis was one of the top stories in gastroenterology last week.

SAN ANTONIO — At this year’s National Liver Congress, Gideon M. Hirschfield, MD, presented real-life cases of patients with primary sclerosing cholangitis along with an overview of how autoimmune liver disease may change over time from initial presentation.

The FDA has selected the Crohn’s & Colitis Foundation as one of just two patient organizations that will take part in its Real-World Evidence Program using the MyStudies App, which will allow the foundation to expand research and data systems, according to a press release.

In the United Kingdom, the prevalence of inflammatory bowel disease has increased significantly since 2000 and is expected to keep rising, according to study results presented at UEG Week.

The FDA on Monday approved Stelara for the treatment of adults with moderately to severely active ulcerative colitis, according to a press release from the manufacturer.

CHICAGO — Two endoscopic scoring indices originally designed for use in adults are reliable for the assessment of endoscopic in children with ulcerative colitis, according to research presented at NASPGHAN 2019.

Experts on fecal microbiota transplantation from Europe, North America and Australia have released a new consensus report that provides guidance on how to establish, operate and regulate stool banks.

The Bruce and Cynthia Sherman Charitable Foundation has announced the 2019 recipients of the Sherman Prize for their research in the treatment of Crohn’s disease and ulcerative colitis.

In a Q&A with Healio, gastroenterologists shared how they are handling the recent Zantac recalls in their practices, and Cologuard — a noninvasive colorectal cancer screening test — received FDA approval for at-risk individuals aged 45 years or older.